Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2019-06-19 Regulatory Filings
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) meeting/presentation. It provides details such as the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a regulatory filing announcement regarding an event.
2019-06-19 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제3회차)
Capital/Financing Update Classification · 95% confidence The document is an official regulatory filing from the Korean Exchange (KRX) regarding the acquisition of convertible bonds before maturity by the company Antrogen. It details the specific bond series, acquisition amount, date, and reason (early redemption request). This falls under capital structure and financing updates, specifically related to debt instruments.
2019-06-12 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) meeting scheduled for May 22, 2019. It provides details such as the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory announcement.
2019-05-20 Korean
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is an official regulatory filing from a Korean company (Antrogen) detailing the adjustment of the conversion price for convertible bonds due to a decline in the stock price. This type of disclosure regarding changes to capital structure, specifically conversion price adjustments for debt instruments, falls under the 'Capital/Financing Update' category.
2019-05-20 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '안트로젠' (Anterogen) covering the period from 2019.01.01 to 2019.03.31. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-14 Korean
신규시설투자등(자율공시)
Capital/Financing Update Classification · 95% confidence The document is a regulatory disclosure from the company 'Antrogen' regarding a 'New Facility Investment' (신규시설투자). It details the investment amount, purpose (GMP manufacturing facility construction), and board approval date. This type of disclosure, which informs the market about specific corporate capital expenditure decisions, falls under the category of general regulatory announcements as it does not fit into specific categories like M&A or share issues.
2019-04-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.